Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma regains China rights to Nerlynx and amends deal with Fabre
Partners of the Pierre Fabre Group: from health to beauty
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre engagements | NERLYNX
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Fight against cancer : our therapeutic responses | Pierre Fabre
